| Date | Title | Description |
| 12.11.2025 | RFK Jr.’s FDA Is Now Also In Turmoil Over Corrupt Drug Regulator | While we’ve talked quite a bit about the horror show that is RFK Jr.’s position as Secretary of HHS, most of the focus of those posts has been around what is happening at the CDC. And for good reason, too. The ongoing measles outbreak, the ... |
| 03.11.2025 | FDA’s top drug regulator resigns after federal officials probe ‘serious concerns’ | By MATTHEW PERRONE, Associated Press
WASHINGTON (AP) — The head of the Food and Drug Administration’s drug center abruptly resigned Sunday after federal officials began reviewing “serious concerns about his personal conduct,” according to a... |
| 21.05.2024 | ILJIN SNT Co., Ltd. Calls for Board Restructure at Aurinia Pharmaceuticals | SEOUL, South Korea, May 21, 2024 /PRNewswire/ --
Fellow Aurinia Shareholders,
ILJIN SNT Co., Ltd. and its affiliates (collectively, "ILJIN") is a long-term holder of more than 5% of Aurinia Pharmaceuticals Inc. ("Aurinia"... |
| 09.08.2021 | Here are your 2021 Life Sciences BC Award winners | Dr. Carl Hansen, CEO, AbCellera
Life Sciences BC (LSBC) announced the recipients of the 23rd Annual Life Sciences BC Awards. Every year, the awards recognize individuals and organizations who contribute to the vibrant life sciences ecosyste... |
| 02.03.2021 | Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences | VICTORIA, British Columbia--(BUSINESS WIRE)--Mar 2, 2021--
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in multiple upcoming investor c... |
| 24.02.2021 | Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights | VICTORIA, British Columbia--(BUSINESS WIRE)--Feb 24, 2021--
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the fourth quarter and year ended December 31, 2020. Amou... |
| 18.02.2021 | Catalent Announces Commercial Supply Agreement with Aurinia Pharmaceuticals for Newly-Approved LUPKYNIS™ Softgels | Catalent has a long track record in bringing novel drugs to market, and has supported over 80% of all prescription pharmaceutical softgel brand launches in the U.S.
SOMERSET, N.J. (PRWEB) February 18, 2021
Catalent, the leading global provi... |
| 25.01.2021 | FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis | Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved LUPKYNISTM (voclosporin) in combination with a background immunosuppressive th... |
| 16.03.2020 | Aurinia Initiates rolling Submission of NDA to U.S. FDA | VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announc... |
| 12.03.2020 | Aurinia Partners with National Kidney Foundation on Awareness Initiative | VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and... |
| 25.02.2020 | Aurinia Appoints New Chief Commercial Officer & Expands U.S. Leadership | VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today a... |
| 12.12.2019 | Aurinia Closes $191.7M Public Offering of Common Shares | VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today a... |
| 09.12.2019 | Aurinia Prices US$166.7M Public Offering of Common Shares | VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today a... |
| 05.12.2019 | Putting the safety issue to bed, Aurinia's late-stage lupus nephritis data shines | After a checkered mid-stage program marred by patient deaths, Aurinia emerged victorious on Wednesday with Phase III lupus nephritis data that demonstrated its lead drug is safe and effective for a patient population tha... |
| 04.12.2019 | Aurinia Demonstrates Voclosporin’s Superiority over Standard-of-Care in Lupus Nephritis | VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory an... |
| 14.11.2019 | Aurinia Pharmaceuticals Releases Q3 2019 Financial Update | VICTORIA, British Columbia — (BUSINESS WIRE) — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, tod... |
| 13.11.2019 | Aurinia Appoints Sr. Finance Executive to Board of Directors | VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory a... |
| 07.11.2019 | Aurinia Pharmaceuticals Completes Voclosporin Study | VICTORIA, British Columbia — (BUSINESS WIRE) — Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory ... |
| 31.10.2019 | Aurinia Initiates Patient Dosing in Dry Eye Syndrome Clinical Trial | VICTORIA, British Columbia — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune co... |
| 17.10.2019 | Aurinia Completes Last Patient Study Visit in AURORA Phase 3 Lupus Nephritis Study & Provides Update on ATM Facility | VICTORIA, British Columbia–(BUSINESS WIRE) — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory a... |
| 13.09.2019 | Aurinia Pharmaceuticals Enters into Agreement with Jefferies LLC. | VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today ... |
| 06.08.2019 | Aurinia Releases Q2 2019 Financial Results | Related Article: Aurinia Reports First Quarter 2019 Financial Results & Recent Operational Highlights |
| 18.07.2019 | Aurinia Strengthens Its Senior Management Team with the Appointment of Max Donley & Dr. Glenn Schulman | “It is a pleasure to welcome Max and Glenn to the team at this critical juncture for Aurinia. As we continue to build and expand the organization and prepare for the potential U.S. commercialization of voclosporin, their respective talents ... |
| 27.06.2019 | Shareholders Overwhelmingly Support Aurinia & Its Board of Directors | Dissident Withdraws the Consents of its Nominees from Consideration Prior to the AGM |
| 14.05.2019 | Aurinia Reports First Quarter 2019 Financial Results and Recent Operational Highlights | VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reported financial results for the first quarter ended March 31, 2019, and provided an update on recent ope... |
| 03.05.2019 | Aurinia Further Strengthens Its Board of Directors with the Appointment of Dr. Daniel Billen | Press Release: April 30, 2019 |
| 11.04.2019 | Aurinia Pharmaceuticals Inc. Announces New CEO and Board Director and Appoints New Chairman of the Board | VICTORIA, British Columbia–(BUSINESS WIRE) — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late clinical-stage biopharmaceutical company focused on the global immunology market, today announced the a... |
| 14.03.2019 | Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease | VICTORIA, British Columbia (BUSINESS WIRE) — In recognition of World Kidney Day and National Kidney Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a late clinical-stage biopharmaceutical company with research ongoing in two ki... |
| 25.02.2019 | Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis | VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/ TSX:AUP) (the “Company” or “Aurinia”), a clinical-stage biopharmaceutical company focused on the global immunology market, today announced that it has re... |
| 22.01.2019 | Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome | VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced positive results for its exploratory Phase 2... |
| 25.09.2018 | Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis | -Target enrollment has been exceeded and completed ahead of schedule |
| 30.07.2018 | Aurinia Pharmaceuticals to Release Second Quarter 2018 Financial Results on August 9, 2018 | VICTORIA, British Columbia– Aurinia Pharmaceuticals Inc. today announced that it will release its second quarter 2018 financial results on Thursday, August 9, 2018, after the market closes. Aurinia’s management will host a conference call t... |
| 11.07.2018 | Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome | VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluat... |
| 25.06.2018 | Aurinia Initiates Clinical Trials Broadening the Development of Voclosporin | VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the enrollment of the first patients into the... |
| 20.02.2018 | Aurinia Named Company of the Year by LifeSciences BC | VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced it has received this year’s Company of the Year Award from LifeSciences BC. The 2018 LifeSciences BC award winners will be re... |
| 17.01.2018 | Term Sheet — Wednesday, January 17 | 5 Qs WITH A DEALMAKER
Krishna Yeshwant is not your typical VC. In addition to practicing internal medicine, Yeshwant is a general partner at GV (formerly Google Ventures), where he heads the Life Sciences team. His portfolio includes compan... |
| 20.03.2017 | Aurinia Closes US$173.1 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares | VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the closing o... |
| 01.03.2017 | Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study | Learn More-External Link |
| 27.01.2017 | Everyone everywhere could only dream of a customer like this | By design, those quotes from customers are planned and canned.
So it was quite a departure from the ordinary to meet Robert Huizinga, vice president of clinical affairs, Aurinia Pharmaceuticals during the J.P. Morgan Healthcare Conference i... |
| 29.09.2016 | Aurinia Announces That Voclosporin Achieves Primary and All Pre-Specified Secondary Endpoints in Its Phase 2b AURA-LV Study for Lupus Nephritis (LN) | VICTORIA, British Columbia–September 29, 2016: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”) a clinical stage biopharmaceutical company focused on the global immunology market, today announced that in add... |
| 24.11.2015 | Aurinia Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis – Study to Continue as Planned | November 24, 2015 08:30 AM Eastern Standard Time
VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH-TSX:AUP) (“Aurinia” or the “Company”) has announced today that the independent Data and Safety Monitoring ... |
| 03.03.2015 | Vascular Pharmaceuticals, Inc. Completes $9.0 Million Expansion of Series A Financing | CHAPEL HILL, N.C., March 5, 2015 –Vascular Pharmaceuticals, Inc. (VPI), a clinical-stage pharmaceutical company addressing the complications of diabetes, announced today that it has increased its Series A financing with the addition of a $9... |
| 14.02.2014 | Aurinia Announces US$52 Million Private Placement | VICTORIA, British Columbia, Feb. 14, 2014 (GLOBE NEWSWIRE) — Aurinia Pharmaceuticals Inc. (TSX-V:AUP) (“Aurinia” or the “Company”) today announced that it has completed, subject to regulatory approval, a US$52 million private placement (the... |
| - | Everyone everywhere could only dream of a customer like this | In the business world, customer testimonials are gold especially for young startups hoping to open doors and grow.
They typically appear as one sentence kudos on the startup’s or business’s website or in press releases blessed by the market... |
| - | Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report | VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Mar 15, 2021--
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today announced a favorable assessment regarding the cost-effectiveness and val... |
